Source-grounded facts extracted from UroGen Pharma Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
UroGen Pharma Ltd. reported the first quarter ended March 31, 2026 results: revenue ZUSDURI™ generated revenue of $29.2 million in Q1 2026.
“On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
UroGen Pharma Ltd. incurred term loan of up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC at 8.25% per annum fixed maturing 5th year anniversary of the Tranche A Closing Date.
“On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).”
UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).
“On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).”
Christopher Degnan was appointed as Chief Financial Officer at UroGen Pharma Ltd..
“the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.”
Don Kim resigned as Chief Financial Officer at UroGen Pharma Ltd..
“pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024”
Fred E. Cohen resigned as Director at UroGen Pharma Ltd..
“On September 12, 2024, Fred E. Cohen, M.D., D.Phil., notified UroGen Pharma Ltd. (the “Company”) of his resignation as a director of the Company, effective immediately.”
UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.
“• Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat”
UroGen Pharma Ltd. reported the full year 2023 results: revenue $82.7 million.
“Net JELMYTO product revenue for the full year 2023 was $82.7 million, compared to $64.4 million in 2022.”
UroGen Pharma Ltd. reported the fourth quarter of 2023 results: revenue $23.5 million.
“UroGen reported JELMYTO net product revenues of $23.5 million in the fourth quarter of 2023, compared to $18.1 million for the same period in 2023.”
UroGen Pharma Ltd. entered into Agreement with Medac Gesellschaft für klinische Spezialpräparate m.b.H. (effective 2024-01-16).
“On January 16, 2024, UroGen Pharma Ltd. (the “Company”) entered into a license and supply agreement (the “Agreement”) with Medac Gesellschaft für klinische Spezialpräparate m.b.H. (“medac”), pursuant to which medac granted to the Company an exclusive, worldwide, royalty-free, sublicensable license under medac’s intellectual property rights to develop, commercialize, import, export, use, distribute and register the pharmaceutical lyophilized product—a specific 80 mg formulation of mitomycin and 640 mg urea, manufactured according to medac’s proprietary lyophilization process (the “Product”)—as an integrated part of a pharmaceutical product that includes the Product and a reverse thermal gel, including the Company’s RTGel® reverse thermal hydrogels (the “Combined Product”).”
UroGen Pharma Ltd. amended Amendment No. 2 to Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. valued at approximately €4.4 million (effective 2023-12-28).
“On December 28, 2023, UroGen Pharma Ltd. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to its Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. (“Cenexi”), dated as of April 24, 2020 and amended as of March 2, 2022 (as amended by the Amendment, the “Agreement”).”
UroGen Pharma Ltd. reported the third quarter ended September 30, 2023 results: revenue $20.9 million, net income a net loss of $21.9 million, EPS basic and diluted net loss per ordinary share of $0.68. Guidance reaffirmed.
“--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 UroGen Pharma Reports Third Quarter 2023 Financial Results • Continued strong growth with JELMYTO ® net product revenues of $20.9 million in Q3 2023; an increase of ~30% from the same period last year • Agreement with United States Food & Drug Administration (FDA) to proceed with rolling New Drug Application (NDA)”
UroGen Pharma Ltd. shareholders approved Engagement of PricewaterhouseCoopers LLP as independent auditor.
“Proposal 5 - Engagement of PricewaterhouseCoopers LLP as independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company’s independent auditor until the Company’s 2024 annual meeting of shareholders.”
UroGen Pharma Ltd. shareholders approved Advisory vote on the compensation of the Company’s named executive officers.
“Proposal 4 - Advisory vote on the compensation of the Company’s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting.”
UroGen Pharma Ltd. shareholders approved Performance Stock Units grant to CEO.
“Proposal 3 – Performance Stock Units The shareholders approved a grant of Performance Stock Units to the Company’s Chief Executive Officer under the 2017 Amended Plan.”
UroGen Pharma Ltd. shareholders approved 2017 Amended Plan.
“Proposal 2 – 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.”
UroGen Pharma Ltd. shareholders approved Election of Directors.
“Proposal 1 – Election of Directors The shareholders elected the following eight individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.”
UroGen Pharma Ltd. reported the second quarter ended June 30, 2023 results: revenue $21.1 million.
“UroGen reported net product revenue of JELMYTO for the second quarter 2023 of $21.1 million, compared to $16.6 million in the second quarter of 2022.”
UroGen Pharma Ltd. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $120.0 million (effective 2023-07-26).
“On July 26, 2023, UroGen Pharma Ltd., an Israeli company (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (“Shares”) (or in lieu of Shares, pre-funded warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a pre-funded warrant), in a private placement transaction (the “Private Placement”).”
James A. Robinson Jr. was appointed as Director at UroGen Pharma Ltd..
“appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders”
UroGen Pharma Ltd. reported the first quarter ended March 31, 2023 results: revenue $17.2 million, net income $30.2 million. Guidance reaffirmed.
“99.1 UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments • Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 • Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. May 11,”
UroGen Pharma Ltd. reported the full year ended December 31, 2022 results: revenue $64.4 million.
“Net product revenues were $64.4 million for the full year 2022, compared to $48.0 million for the full year 2021.”
UroGen Pharma Ltd. reported the fourth quarter ended December 31, 2022 results: revenue $18.1 million.
“UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.”
UroGen Pharma Ltd. reported the third quarter ended September 30, 2022 results: revenue $16.1 million.
“invasive bladder cancer (LG-IR-NMIBC) expected as soon as the end of November 2022; NDA submission anticipated in first half of 2024 • Reported JELMYTO ® net product revenue of $16.1 million, an increase of 41% from the same period last year • FDA authorized extension of the in-use period for JELMYTO ® admixture from 8 to 96 hours following reconstitution further”
Daniel G. Wildman was appointed as Director at UroGen Pharma Ltd..
“On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders”
Leana Wen was appointed as Director at UroGen Pharma Ltd..
“On September 8, 2022, Leana Wen, M.D., MSc was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders and was also appointed to the Audit Committee of the Board.”
Dong (Don) Kim was appointed as Chief Financial Officer at UroGen Pharma Ltd..
“Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.”
Molly Henderson resigned as Chief Financial Officer at UroGen Pharma Ltd..
“On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.